Enterprise has developed a pipeline of novel low molecular weight compounds with first-in-class and best-in-class potential – our most advanced drug is ETD001, which targets the ENaC ion channel in the airway epithelium, which is expected to enter Phase 2 clinical trials early-2024.

Program portfolio & status

Low molecular weight mutant agnostic approaches